All News

Found 1,995 articles

• Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

  8/28/2023

  Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, announced the appointment of Jeff Caravella as Chief Financial Officer.

• Innovent Announces 2023 Interim Results and Business Updates

  8/23/2023

  Innovent Biologics, Inc. announces its 2023 interim results and major company business updates.

• Incyte to Present at Upcoming Investor Conferences - August 22, 2023

  8/22/2023

  Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September.

• Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia

  8/16/2023

  Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved SINTBILO®.

• Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results

  8/9/2023

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

• MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

  8/9/2023

  MorphoSys AG reports results for the second quarter and first half year of 2023.

• Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

  8/8/2023

  Syros Pharmaceuticals today reported financial results for the quarter ended June 30, 2023 and provided a corporate update.

• Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update

  8/7/2023

  Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter and provided a business update.

• Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

  8/3/2023

  Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2023 and provided a business update.

• Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer

  8/3/2023

  Deciphera Pharmaceuticals, Inc. announced that the Company’s Founder, Executive Vice President, and Chief Scientific Officer, Daniel L. Flynn, Ph.D., will retire effective September 5, 2023 and will transition to a role as Senior Advisor to the Company.

• Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

  8/3/2023

  Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the quarter ended June 30, 2023, and provided a business update.

• Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

  8/1/2023

  Incyte (Nasdaq:INCY) today reports 2023 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.

• Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

  7/31/2023

  Replimune Group, Inc. (NASDAQ:REPL) and Incyte today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor.

• Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

  7/24/2023

  Syndax Pharmaceuticals (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy. 

• 

  Incyte’s Opzelura Clears Phase III Trial in Pediatric Atopic Dermatitis

  7/12/2023

  The company’s ruxolitinib cream Opzelura led to higher rates of treatment success in children with atopic dermatitis than with a control cream.

• Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

  7/11/2023

  Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream in children with atopic dermatitis.

• Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata

  7/11/2023

  In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia areata.

• Incyte to Report Second Quarter Financial Results - July 11, 2023

  7/11/2023

  Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 1, 2023.

• IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma

  7/3/2023

  IASO Biotechnology and Innovent Biologics, Inc. announced that China National Medical Products Administration has approved the New Drug Application for FUCASO, the world's first fully-human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma who received ≥3 lines of prior therapies containing at least one proteasome inhibitor and an immunomodulatory agent.

• LYMPHOMA THERAPY NOW APPROVED FOR AUSTRALIAN PATIENTS With Diffuse Large B-cell Lymphoma

  6/27/2023

  Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that a new therapy to treat the most common type of non-Hodgkin lymphoma in adults – diffuse large B-cell lymphoma – is now approved for use in Australia.